COVID-19 Impact on Global Cancer Biopharmaceuticals Market Size, Status and Forecast 2020-2026
- BMR3871654
- 129 Pages
- June 2020
- Healthcare
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Cancer Biopharmaceuticals market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Cancer Biopharmaceuticals industry.
Based on our recent survey, we have several different scenarios about the Cancer Biopharmaceuticals YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Cancer Biopharmaceuticals will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Biopharmaceuticals market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Biopharmaceuticals market in terms of revenue.
Players, stakeholders, and other participants in the global Cancer Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Cancer Biopharmaceuticals market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Cancer Biopharmaceuticals market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Biopharmaceuticals market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Biopharmaceuticals market.
The following players are covered in this report:
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Cancer Biopharmaceuticals Breakdown Data by Type
Biologics
Biosimilars
Cancer Biopharmaceuticals Breakdown Data by Application
Liquid Cancers
Solid Cancers
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Cancer Biopharmaceuticals Revenue
1.4 Market Analysis by Type
1.4.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Biologics
1.4.3 Biosimilars
1.5 Market by Application
1.5.1 Global Cancer Biopharmaceuticals Market Share by Application: 2020 VS 2026
1.5.2 Liquid Cancers
1.5.3 Solid Cancers
1.6 Coronavirus Disease 2019 (Covid-19): Cancer Biopharmaceuticals Industry Impact
1.6.1 How the Covid-19 is Affecting the Cancer Biopharmaceuticals Industry
1.6.1.1 Cancer Biopharmaceuticals Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Cancer Biopharmaceuticals Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Cancer Biopharmaceuticals Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Cancer Biopharmaceuticals Market Perspective (2015-2026)
2.2 Cancer Biopharmaceuticals Growth Trends by Regions
2.2.1 Cancer Biopharmaceuticals Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Cancer Biopharmaceuticals Historic Market Share by Regions (2015-2020)
2.2.3 Cancer Biopharmaceuticals Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Cancer Biopharmaceuticals Market Growth Strategy
2.3.6 Primary Interviews with Key Cancer Biopharmaceuticals Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Cancer Biopharmaceuticals Players by Market Size
3.1.1 Global Top Cancer Biopharmaceuticals Players by Revenue (2015-2020)
3.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2015-2020)
3.1.3 Global Cancer Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Cancer Biopharmaceuticals Market Concentration Ratio
3.2.1 Global Cancer Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Cancer Biopharmaceuticals Revenue in 2019
3.3 Cancer Biopharmaceuticals Key Players Head office and Area Served
3.4 Key Players Cancer Biopharmaceuticals Product Solution and Service
3.5 Date of Enter into Cancer Biopharmaceuticals Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Cancer Biopharmaceuticals Historic Market Size by Type (2015-2020)
4.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2021-2026)
5 Cancer Biopharmaceuticals Breakdown Data by Application (2015-2026)
5.1 Global Cancer Biopharmaceuticals Market Size by Application (2015-2020)
5.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Cancer Biopharmaceuticals Market Size (2015-2020)
6.2 Cancer Biopharmaceuticals Key Players in North America (2019-2020)
6.3 North America Cancer Biopharmaceuticals Market Size by Type (2015-2020)
6.4 North America Cancer Biopharmaceuticals Market Size by Application (2015-2020)
7 Europe
7.1 Europe Cancer Biopharmaceuticals Market Size (2015-2020)
7.2 Cancer Biopharmaceuticals Key Players in Europe (2019-2020)
7.3 Europe Cancer Biopharmaceuticals Market Size by Type (2015-2020)
7.4 Europe Cancer Biopharmaceuticals Market Size by Application (2015-2020)
8 China
8.1 China Cancer Biopharmaceuticals Market Size (2015-2020)
8.2 Cancer Biopharmaceuticals Key Players in China (2019-2020)
8.3 China Cancer Biopharmaceuticals Market Size by Type (2015-2020)
8.4 China Cancer Biopharmaceuticals Market Size by Application (2015-2020)
9 Japan
9.1 Japan Cancer Biopharmaceuticals Market Size (2015-2020)
9.2 Cancer Biopharmaceuticals Key Players in Japan (2019-2020)
9.3 Japan Cancer Biopharmaceuticals Market Size by Type (2015-2020)
9.4 Japan Cancer Biopharmaceuticals Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Cancer Biopharmaceuticals Market Size (2015-2020)
10.2 Cancer Biopharmaceuticals Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Cancer Biopharmaceuticals Market Size by Type (2015-2020)
10.4 Southeast Asia Cancer Biopharmaceuticals Market Size by Application (2015-2020)
11 India
11.1 India Cancer Biopharmaceuticals Market Size (2015-2020)
11.2 Cancer Biopharmaceuticals Key Players in India (2019-2020)
11.3 India Cancer Biopharmaceuticals Market Size by Type (2015-2020)
11.4 India Cancer Biopharmaceuticals Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Cancer Biopharmaceuticals Market Size (2015-2020)
12.2 Cancer Biopharmaceuticals Key Players in Central & South America (2019-2020)
12.3 Central & South America Cancer Biopharmaceuticals Market Size by Type (2015-2020)
12.4 Central & South America Cancer Biopharmaceuticals Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Sanofi
13.1.1 Sanofi Company Details
13.1.2 Sanofi Business Overview and Its Total Revenue
13.1.3 Sanofi Cancer Biopharmaceuticals Introduction
13.1.4 Sanofi Revenue in Cancer Biopharmaceuticals Business (2015-2020))
13.1.5 Sanofi Recent Development
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Details
13.2.2 Johnson & Johnson Business Overview and Its Total Revenue
13.2.3 Johnson & Johnson Cancer Biopharmaceuticals Introduction
13.2.4 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.2.5 Johnson & Johnson Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview and Its Total Revenue
13.3.3 Pfizer Cancer Biopharmaceuticals Introduction
13.3.4 Pfizer Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview and Its Total Revenue
13.4.3 Novartis Cancer Biopharmaceuticals Introduction
13.4.4 Novartis Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview and Its Total Revenue
13.5.3 Merck Cancer Biopharmaceuticals Introduction
13.5.4 Merck Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.5.5 Merck Recent Development
13.6 GlaxoSmithKline
13.6.1 GlaxoSmithKline Company Details
13.6.2 GlaxoSmithKline Business Overview and Its Total Revenue
13.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Introduction
13.6.4 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.6.5 GlaxoSmithKline Recent Development
13.7 Eli Lilly
13.7.1 Eli Lilly Company Details
13.7.2 Eli Lilly Business Overview and Its Total Revenue
13.7.3 Eli Lilly Cancer Biopharmaceuticals Introduction
13.7.4 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.7.5 Eli Lilly Recent Development
13.8 Agios Pharmaceuticals
13.8.1 Agios Pharmaceuticals Company Details
13.8.2 Agios Pharmaceuticals Business Overview and Its Total Revenue
13.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Introduction
13.8.4 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.8.5 Agios Pharmaceuticals Recent Development
13.9 Bristol-Myers Squibb
13.9.1 Bristol-Myers Squibb Company Details
13.9.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Introduction
13.9.4 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.9.5 Bristol-Myers Squibb Recent Development
13.10 AstraZeneca
13.10.1 AstraZeneca Company Details
13.10.2 AstraZeneca Business Overview and Its Total Revenue
13.10.3 AstraZeneca Cancer Biopharmaceuticals Introduction
13.10.4 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2015-2020)
13.10.5 AstraZeneca Recent Development
13.11 Mylan
10.11.1 Mylan Company Details
10.11.2 Mylan Business Overview and Its Total Revenue
10.11.3 Mylan Cancer Biopharmaceuticals Introduction
10.11.4 Mylan Revenue in Cancer Biopharmaceuticals Business (2015-2020)
10.11.5 Mylan Recent Development
13.12 LEO Pharma
10.12.1 LEO Pharma Company Details
10.12.2 LEO Pharma Business Overview and Its Total Revenue
10.12.3 LEO Pharma Cancer Biopharmaceuticals Introduction
10.12.4 LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2015-2020)
10.12.5 LEO Pharma Recent Development
13.13 Boehringer Ingelheim
10.13.1 Boehringer Ingelheim Company Details
10.13.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Introduction
10.13.4 Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2015-2020)
10.13.5 Boehringer Ingelheim Recent Development
13.14 Alexion Pharmaceuticals
10.14.1 Alexion Pharmaceuticals Company Details
10.14.2 Alexion Pharmaceuticals Business Overview and Its Total Revenue
10.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Introduction
10.14.4 Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2015-2020)
10.14.5 Alexion Pharmaceuticals Recent Development
13.15 Elusys Therapeutics
10.15.1 Elusys Therapeutics Company Details
10.15.2 Elusys Therapeutics Business Overview and Its Total Revenue
10.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Introduction
10.15.4 Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2015-2020)
10.15.5 Elusys Therapeutics Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Cancer Biopharmaceuticals Key Market Segments
Table 2. Key Players Covered: Ranking by Cancer Biopharmaceuticals Revenue
Table 3. Ranking of Global Top Cancer Biopharmaceuticals Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Biologics
Table 6. Key Players of Biosimilars
Table 7. COVID-19 Impact Global Market: (Four Cancer Biopharmaceuticals Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Cancer Biopharmaceuticals Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Cancer Biopharmaceuticals Players to Combat Covid-19 Impact
Table 12. Global Cancer Biopharmaceuticals Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Cancer Biopharmaceuticals Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Cancer Biopharmaceuticals Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Cancer Biopharmaceuticals Market Share by Regions (2015-2020)
Table 16. Global Cancer Biopharmaceuticals Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Cancer Biopharmaceuticals Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Cancer Biopharmaceuticals Market Growth Strategy
Table 22. Main Points Interviewed from Key Cancer Biopharmaceuticals Players
Table 23. Global Cancer Biopharmaceuticals Revenue by Players (2015-2020) (Million US$)
Table 24. Global Cancer Biopharmaceuticals Market Share by Players (2015-2020)
Table 25. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biopharmaceuticals as of 2019)
Table 26. Global Cancer Biopharmaceuticals by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Cancer Biopharmaceuticals Product Solution and Service
Table 29. Date of Enter into Cancer Biopharmaceuticals Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 32. Global Cancer Biopharmaceuticals Market Size Share by Type (2015-2020)
Table 33. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2021-2026)
Table 34. Global Cancer Biopharmaceuticals Market Size Share by Application (2015-2020)
Table 35. Global Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 36. Global Cancer Biopharmaceuticals Market Size Share by Application (2021-2026)
Table 37. North America Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 39. North America Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 40. North America Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 41. North America Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 42. North America Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 43. Europe Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 45. Europe Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 47. Europe Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 49. China Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 50. China Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 51. China Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 52. China Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 53. China Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 54. China Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 55. Japan Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 57. Japan Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 59. Japan Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 63. Southeast Asia Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 65. Southeast Asia Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 67. India Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 68. India Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 69. India Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 70. India Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 71. India Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 72. India Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Cancer Biopharmaceuticals Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Cancer Biopharmaceuticals Market Share (2019-2020)
Table 75. Central & South America Cancer Biopharmaceuticals Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Cancer Biopharmaceuticals Market Share by Type (2015-2020)
Table 77. Central & South America Cancer Biopharmaceuticals Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Cancer Biopharmaceuticals Market Share by Application (2015-2020)
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi Product
Table 82. Sanofi Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 83. Sanofi Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Product
Table 87. Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 88. Johnson & Johnson Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Product
Table 97. Novartis Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 98. Novartis Recent Development
Table 99. Merck Company Details
Table 100. Merck Business Overview
Table 101. Merck Product
Table 102. Merck Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 103. Merck Recent Development
Table 104. GlaxoSmithKline Company Details
Table 105. GlaxoSmithKline Business Overview
Table 106. GlaxoSmithKline Product
Table 107. GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 108. GlaxoSmithKline Recent Development
Table 109. Eli Lilly Company Details
Table 110. Eli Lilly Business Overview
Table 111. Eli Lilly Product
Table 112. Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 113. Eli Lilly Recent Development
Table 114. Agios Pharmaceuticals Business Overview
Table 115. Agios Pharmaceuticals Product
Table 116. Agios Pharmaceuticals Company Details
Table 117. Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 118. Agios Pharmaceuticals Recent Development
Table 119. Bristol-Myers Squibb Company Details
Table 120. Bristol-Myers Squibb Business Overview
Table 121. Bristol-Myers Squibb Product
Table 122. Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 123. Bristol-Myers Squibb Recent Development
Table 124. AstraZeneca Company Details
Table 125. AstraZeneca Business Overview
Table 126. AstraZeneca Product
Table 127. AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 128. AstraZeneca Recent Development
Table 129. Mylan Company Details
Table 130. Mylan Business Overview
Table 131. Mylan Product
Table 132. Mylan Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 133. Mylan Recent Development
Table 134. LEO Pharma Company Details
Table 135. LEO Pharma Business Overview
Table 136. LEO Pharma Product
Table 137. LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 138. LEO Pharma Recent Development
Table 139. Boehringer Ingelheim Company Details
Table 140. Boehringer Ingelheim Business Overview
Table 141. Boehringer Ingelheim Product
Table 142. Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 143. Boehringer Ingelheim Recent Development
Table 144. Alexion Pharmaceuticals Company Details
Table 145. Alexion Pharmaceuticals Business Overview
Table 146. Alexion Pharmaceuticals Product
Table 147. Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 148. Alexion Pharmaceuticals Recent Development
Table 149. Elusys Therapeutics Company Details
Table 150. Elusys Therapeutics Business Overview
Table 151. Elusys Therapeutics Product
Table 152. Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2015-2020) (Million US$)
Table 153. Elusys Therapeutics Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Biopharmaceuticals Market Share by Type: 2020 VS 2026
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Cancer Biopharmaceuticals Market Share by Application: 2020 VS 2026
Figure 5. Liquid Cancers Case Studies
Figure 6. Solid Cancers Case Studies
Figure 7. Cancer Biopharmaceuticals Report Years Considered
Figure 8. Global Cancer Biopharmaceuticals Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Cancer Biopharmaceuticals Market Share by Regions: 2020 VS 2026
Figure 10. Global Cancer Biopharmaceuticals Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Cancer Biopharmaceuticals Market Share by Players in 2019
Figure 13. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biopharmaceuticals as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Cancer Biopharmaceuticals Revenue in 2019
Figure 15. North America Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Cancer Biopharmaceuticals Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. Sanofi Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 24. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Johnson & Johnson Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 26. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Pfizer Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 28. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Novartis Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 30. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Merck Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 32. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. GlaxoSmithKline Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 34. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Eli Lilly Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 36. Agios Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Agios Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 38. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Bristol-Myers Squibb Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 40. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. AstraZeneca Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 42. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Mylan Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 44. LEO Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. LEO Pharma Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 46. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Boehringer Ingelheim Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 48. Alexion Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Alexion Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 50. Elusys Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Elusys Therapeutics Revenue Growth Rate in Cancer Biopharmaceuticals Business (2015-2020)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
